Evidence map›Paper›PMID 34771534›Full record

ArticleCancers2021

Application of High-Z Gold Nanoparticles in Targeted Cancer Radiotherapy-Pharmacokinetic Modeling, Monte Carlo Simulation and Radiobiological Effect Modeling.

Wei Bo Li, Stefan Stangl, Alexander Klapproth, Maxim Shevtsov, Alicia Hernandez, Melanie A Kimm, Jan Schuemann, Rui Qiu, Bernhard Michalke, Mario A Bernal and 4 more

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Shape-Driven Response of Gold Nanoparticles to X-rays.Nanomaterials (Basel, Switzerland) · 2023
    Article
  7. Review
  8. Scientific Basics of Personalized Medicine: Realities and Opportunities.Herald of the Russian Academy of Sciences · 2022
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wei Bo LiInstitute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany.ORCID 0000-0002-9802-4400
Stefan StanglCenter for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany.ORCID 0000-0002-0439-8007
Alexander KlapprothInstitute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany.ORCID 0000-0001-8650-8451
Maxim ShevtsovCenter for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany.
Alicia HernandezCenter for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany.
Melanie A KimmDepartment of Diagnostic and Interventional Radiology, Technische Universität München (TUM), Klinikum Rechts der Isar, 81675 Munich, Germany.ORCID 0000-0001-6833-9738
Jan SchuemannPhysics Division, Department of Radiation Oncology, Massachusetts General Hospital (MGH) & Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-7554-8818
Rui QiuDepartment of Engineering Physics, Tsinghua University, Beijing 100084, China.
Bernhard MichalkeResearch Unit Analytical BioGeoChemistry, Helmholz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany.ORCID 0000-0001-6376-2588
Mario A BernalGleb Wataghin Institute of Physics, State University of Campinas, Campinas 13083-859, SP, Brazil.
Junli LiDepartment of Radiology, University Hospital, Ludwig-Maximilians-Universität München, 81337 Munich, Germany.
Kerstin HürkampInstitute of Radiation Medicine, Helmholtz Zentrum München-German Research Center for Environmental Health (GmbH), 85764 Neuherberg, Germany.
Yibao ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Gabriele MulthoffCenter for Translational Cancer Research, Technische Universität München (TranslaTUM), Klinikum Rechts der Isar, Einsteinstr. 25, 81675 Munich, Germany.

Funding

TOPAS - nBio, a Monte Carlo tool for radiation biology researchR01CA187003 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SCHUEMANN, JAN PATRICK OSCAR · 2015 to 2024
$4.8M
Deutsche Forschungsgemeinschaft SFB824/3, STA1520/1-1National Institutes of Health (NIH)/National Cancer Institute (NCI) R01 CA187003.NCI NIH HHS R01 CA187003The Ministry of Science and Higher Education of the Russian Federation 075-15-2020-901
6 · The paper itself

Abstract

High-Z gold nanoparticles (AuNPs) conjugated to a targeting antibody can help to improve tumor control in radiotherapy while simultaneously minimizing radiotoxicity to adjacent healthy tissue. This paper summarizes the main findings of a joint research program which applied AuNP-conjugates in preclinical modeling of radiotherapy at the Klinikum rechts der Isar, Technical University of Munich and Helmholtz Zentrum München. A pharmacokinetic model of superparamagnetic iron oxide nanoparticles was developed in preparation for a model simulating the uptake and distribution of AuNPs in mice. Multi-scale Monte Carlo simulations were performed on a single AuNP and multiple AuNPs in tumor cells at cellular and molecular levels to determine enhancements in the radiation dose and generation of chemical radicals in close proximity to AuNPs. A biologically based mathematical model was developed to predict the biological response of AuNPs in radiation enhancement. Although simulations of a single AuNP demonstrated a clear dose enhancement, simulations relating to the generation of chemical radicals and the induction of DNA strand breaks induced by multiple AuNPs showed only a minor dose enhancement. The differences in the simulated enhancements at molecular and cellular levels indicate that further investigations are necessary to better understand the impact of the physical, chemical, and biological parameters in preclinical experimental settings prior to a translation of these AuNPs models into targeted cancer radiotherapy.

Indexed as

cancerscmHsp70.1conjugationenhancement effectgold nanoparticlesMonte Carlo simulationpharmacokinetic modelradiobiological modelingtargeted radiotherapyX-rays

Identifiers

PMID34771534
PMCPMC8582555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.